MOONLAKE IMMUNOTHERAPEUTICS (MLTX)
KY61559X1045 - Common Stock
MOONLAKE IMMUNOTHERAPEUTICS
NASDAQ:MLTX (9/28/2023, 7:01:04 PM)
After market: 56.66 0 (0%)56.66
+1.12 (+2.02%)
Company Profile
Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. The company is headquartered in Zug, Zug and currently employs 20 full-time employees. The company went IPO on 2020-10-20. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The firm develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
Company Info
MOONLAKE IMMUNOTHERAPEUTICS
Dorfstrasse 29
Zug ZUG
P: 41415108022.0
Employees: 20
MLTX News
a day ago - InvestorPlace7 ‘Strong Buy’ Biotech Stocks to Rejuvenate Your PortfolioDive into these seven strong buy biotech stocks, handpicked by Wall Street, to inject vigor into your investment game.
11 days ago - Investor's Business DailyThese 8 Stocks Are Outperforming Nvidia In 2023Carvana has surged 1,001%, leading huge winners this year.
11 days ago - Seeking AlphaAcelyrin, MoonLake rivalry heats up as both chase blockbuster PsA marketThe rivalry between Acelyrin (SLRN) and MoonLake (MLTX) is heating up, with both companies slated to report key data on their drugs for psoriatic arthritis, or PsA. Read more here.
16 days ago - The Motley FoolWhy Shares of MoonLake Immunotherapeutics Are Rising TuesdayA competitor's clinical trial stumble may be benefiting MoonLake.
17 days ago - Investor's Business DailyThe Surprising Acelyrin News That Sent Rival MoonLake, A Top 1% Stock, Soaring 19%The companies are both working on treatments for a rare skin disease.
17 days ago - Seeking AlphaAcelyrin tanks, rival MoonLake rallies on failed clinical trial (SLRN)Acelyrin (SLRN) stock tanked in after-hours trading Monday after the company said its lead drug izokibep failed a mid-stage clinical trial, stoking shares of rival MoonLake (MLTX).
MLTX Twits
Here you can normally see the latest stock twits on MLTX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
